Moderna Stock Nearly Tripled On A Personalized Cancer Vaccine Then Gave Much Of It Back

Moderna shares did something on Wall Street last week that a single vaccine maker rarely manages twice: they nearly tripled in a single trading session. The stock jumped 176.97 percent in one day, from $62.96 to $174.38, adding roughly $40 billion to the company's market value before gravity reasserted itself. Within days the rally had cooled sharply, with shares sliding more than 20 percent back below $137, leaving traders to debate how much of the move reflected a genuine scientific breakthrough and how much reflected a stock that had been heavily bet against finally snapping back.

The trigger was a Phase 3 trial result for an experimental skin cancer treatment that pairs Moderna's messenger RNA technology with Merck's blockbuster immunotherapy Keytruda. The combination, known as intismeran autogene, or mRNA-4157, is designed as a personalized cancer vaccine built individually for each patient rather than manufactured as a one size fits all product. In a trial enrolling 1,137 patients with high risk melanoma who had already had their tumors surgically removed, the combination met both of its pre-specified goals, extending the time patients lived without their cancer returning and, according to the companies, showing an early signal on overall survival as well.

What sets intismeran autogene apart from Moderna's original COVID-19 shot is that it is not mass produced. After a tumor is removed, its genetic material is sequenced to identify the specific mutations unique to that patient's cancer. An algorithm then selects the mutations most likely to trigger an immune response, and Moderna manufactures a customized mRNA vaccine encoding those exact targets, essentially teaching the patient's own immune system to hunt down any cancer cells that were left behind after surgery. Paired with Keytruda, which works by releasing the brakes the immune system normally puts on itself, the approach amounts to a "one person, one drug" model of cancer care, a proposition that has excited investors far beyond the confines of oncology.

The scientific foundation for last week's rally was not entirely new. Moderna and Merck had already published five year follow up data from the earlier Phase 2 trial of the same combination, showing a 49 percent relative reduction in the risk of cancer recurrence, death or spread, and a 59 percent relative reduction in the risk of the cancer spreading to distant parts of the body, compared with Keytruda alone. Those numbers sound dramatic, but oncologists are quick to note that a relative risk reduction measures the gap between two small numbers, and can look far more impressive than the actual difference in how many patients benefit. Without the underlying absolute rates, in other words, a "49 percent reduction" could describe anything from a modest single digit improvement to a much larger one.

That caveat found a prominent messenger in Taiwan. Academia Sinica academician Chen Pei-jer (陳培哲), a veteran of the island's clinical research community, was measured in his assessment of what the new data actually shows. He noted that meeting the trial's two pre-specified endpoints is a real and meaningful result, but cautioned against reading a single readout as proof that personalized mRNA cancer vaccines have arrived as a mainstream therapy. What clinicians still need, he said, are the harder numbers: the hazard ratio describing the treatment's actual effect size, the absolute difference in outcomes between patients who received the combination and those who did not, and, eventually, mature overall survival data showing that patients are not just living longer without a relapse but living longer, period.

Chen's caution echoes a broader pattern in oncology drug development, where early endpoints such as recurrence free survival can move a stock price long before they translate into a proven survival benefit. Regulators typically want to see that longer term survival data before granting full approval, a process that in this case is still ongoing even as investors have already rendered their verdict.

Part of what made the rally so violent was the positioning already built into Moderna's stock before the trial results landed. Short interest, the share of Moderna's outstanding stock that traders had borrowed and sold in bets that the price would fall, stood at roughly 13.7 percent heading into the announcement, an unusually crowded short position for a company of Moderna's size. When the trial data beat expectations, those short sellers were forced to buy back shares to close out their losing bets, a scramble that mechanically pushed the price higher on top of whatever genuine optimism the science itself generated. That short squeeze dynamic helps explain both the size of the initial spike and the speed of the pullback that followed, as some of the buying was less a vote of confidence in Moderna's long term pipeline than a rush by short sellers to limit their losses, followed by profit taking once the panic subsided.

For Moderna, the episode captures the gap between how investors and how physicians are inclined to price a scientific announcement. To the market, intismeran autogene is proof of concept for an entire platform, evidence that the same mRNA manufacturing infrastructure built for COVID-19 vaccines can be repointed at cancer, with each new trial readout treated as a milestone for the technology itself rather than just for one drug. To oncologists like Chen, the same announcement is one data point in a much longer process, one that still needs hazard ratios, absolute risk differences and, ultimately, confirmed survival benefits before it changes how melanoma patients are actually treated. Both readings can be true at once, which is part of why a single trial update was enough to move $40 billion in market value in a single afternoon, and to give a large fraction of it back a few days later.

Original Article in Chinese （Related： Tzu Chi Lost $38 Million to Vaccine Fraudsters and Never Noticed for Five Years ｜ Latest ）